InvestorsHub Logo
Followers 13
Posts 1084
Boards Moderated 0
Alias Born 08/03/2017

Re: Katloose post# 2460

Monday, 01/11/2021 1:03:23 PM

Monday, January 11, 2021 1:03:23 PM

Post# of 9427
Right! It was just odd that they sent an email with News round up. News Roundup
What’s Next For Mindmed After They Close Their Upsized $92.1 Million Financing (JR Rahn Interview)
"We have a federally regulated approach. This is the main thing that CIBC was looking at; they wanted nothing to do with state-by-state legalization efforts, they wanted nothing to do with recreational market. Federal compliance is going to be super important."
See original video here


Is it time to rehabilitate psychedelics?

"JR Rahn is the founder of MindMed, a New York-based startup, which is developing psychedelic drugs to treat mental illness and addiction. 'Translating this science into scalable medicines,' he says."
See original article here

Why The Psychedelics Market Is NOT Cannabis 2.0
"Psychedelics, however, offer hundreds of various molecules that can be developed, tested, and deployed through the same process biotech companies and Big Pharma develop, test, and deploy their products into the marketplace. And it doesn’t take a rocket scientist to know that if you latch onto the right biotech or pharma play, that has the right product, you can easily see 10, 20, 30X returns. It happens all the time, and I foresee the psychedelics market playing out the same way."
See original article here

Mind Medicine: Why Kevin O'Leary Thinks This Psychedelics Company Is Just Getting Started
"Shark Tank star Kevin O'Leary has invested in hundreds of businesses over the years, some on-screen and some off. But few have attracted as much attention as his investment in psychedelic drug company Mind Medicine (OTC:MMED.F), also known as MindMed."
See original article here


Everyone said 'no' to MindMed, now it's worth $2 billion with 'unicorn' status

"MindMed (MMED.NE) has surpassed the $2 billion market cap on Monday when shares surged 35% by midday. Year-to-date, the company’s stock more than 10 times, from 53 cents in March to $5.60 by the end of the trading day.

Institutional investors are starting to come into the psychedelic drug space because the danger of mental health issues is becoming a serious problem for society."
See original article here


The Case for Macrodosing

"The US military is funding research into psychedelic compounds that don’t make you trip and Canadian pharmaceutical company MindMed is developing a psychedelic off-switch, as examples."
See original article here
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNMD News